AI assistant
Niagen Bioscience, Inc. — Director's Dealing 2014
Mar 10, 2014
32418_dirs_2014-03-10_10f5298d-b6fd-42ef-869d-1865f5adb167.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2014-03-06
Reporting Person: Rhonemus Troy Allen (N/A)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Options (right to buy) | $0.63 | 2023-01-25 | Common Stock (200000) | Direct | |
| Employee Stock Options (right to buy) | $0.63 | 2023-01-25 | Common Stock (200000) | Direct | |
| Employee Stock Options (right to buy) | $1.75 | 2024-02-21 | Common Stock (250000) | Direct |
Footnotes
F1: 1/4th of the options vested on January 25, 2014 with the remainder vesting 1/36th per month over the three years thereafter. Options will be fully vested as of January 25, 2017.
F2: 1/4th of the options vest on January 25, 2014 with the remainder vesting 1/36th per month over the three years thereafter. However, in additioin, the exercisability of these options is subject to achievement of certain goals.
F3: 1/3rd of the options will vest on February 21, 2015 with the remainder vesting 1/24th per month over the two years thereafter. Options will be fully vested as of February 21, 2017.